GT20029 IND Was Accepted by NMPA

(Summary description)

GT20029 IND Was Accepted by NMPA

(Summary description)

Information
Kintor Pharma Announces First Patient Dosing of Phase III Clinical Trial of KX-826 for Treating Androgenic Alopecia Patients in China
Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma
Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Androgenetic Alopecia Was Met
Kintor Pharma Collaborates with Etana to Commercialize Proxalutamide for Treatment of COVID-19 in Indonesia
Kintor Receives EUA for Proxalutamide for the Treatment of COVID-19 in Paraguay
Kintor Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne
Kintor Announced U.S. FDA Has Greenlighted Phase II Clinical Trial for Pyrilutamide to Treat Androgenetic Alopecia
Kintor Announced ANVISA and CONEP in Brazil Approved Proxalutamide's Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor
Kintor Annouced Top-up Placement to Raise USD 150mn
Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19
Kintor Has Expanded Its Geographical Presence to Zhuhai
GT20029 IND Was Accepted by NMPA
Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA

Scan the QR code to read on your phone